Camera Catches Melanoma at Early Stage

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 8
Volume 9
Issue 8

The SIAscope uses light and sophisticated computer software to construct an image of each part of the skin. The technique shows when a mole is invading deeper into the skin than normal, allowing early diagnosis of malignant melanoma. The SIAscope, based on spectrophotometric intracutaneous analysis (SIA), was researched at Birmingham University and developed by Cambridge-based Astron Clinica. It is in clinical trials at various sites in the United Kingdom. Dr. Marc Moncrieff (pictured, left) is one of the doctors conducting the trials.

The SIAscope uses light and sophisticated computer software to construct an image of each part of the skin. The technique shows when a mole is invading deeper into the skin than normal, allowing early diagnosis of malignant melanoma. The SIAscope, based on spectrophotometric intracutaneous analysis (SIA), was researched at Birmingham University and developed by Cambridge-based Astron Clinica. It is in clinical trials at various sites in the United Kingdom. Dr. Marc Moncrieff (pictured, left) is one of the doctors conducting the trials.

Recent Videos
Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.
David Rimm, MD, PhD, discussed how AI tools may help automate routine tasks for pathologists and predict genomic alterations from images.
David Rimm, MD, PhD, shared the rationale behind developing an AI-driven tool for quantifying tumor-infiltrating lymphocytes in melanoma.
The development of multimodal biomarkers may help predict response to immunotherapy among patients with melanoma and other malignancies.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Related Content